5-MAPB

5-MAPB, also known as 5-(N-methyl-2-aminopropyl)benzofuran, as well as by nicknames such as "MDMA 2.0" and "Gas Station Molly", is an entactogen of the phenethylamine, amphetamine, and benzofuran families related to MDMA ("Ecstasy"). It is an analogue of MDMA in which one of the oxygen atoms of the benzodioxole ring has been replaced with a carbon atom. The drug is said to have the closest-known effects to MDMA of any other MDMA analogue, but is said to be less stimulating in comparison and to have less comedown and hangover. In addition, it is more potent than MDMA and has a longer duration. The drug acts as a serotonin–norepinephrine–dopamine releasing agent (SNDRA) similarly to MDMA. It is also an agonist of several serotonin receptors, including the serotonin 5-HT1B, 5-HT2A, 5-HT2B, and 5-HT2C receptors. Some notable analogues of 5-MAPB besides MDMA include other benzofurans like 5-APB, 5-MAPDB, and 6-MAPB. 5-MAPB was first encountered as a novel designer drug in 2013 and was described in the scientific literature in 2014. It is said to have been first synthesized in 2009. The drug has been patented by Tactogen for potential use as a medicine to treat psychiatric disorders. It is openly sold as a legal recreational drug in the United States. In addition to its use by itself, 5-MAPB is used as a component of the more closely MDMA-mimicking Borax combo.